0001213900-23-019602.txt : 20230313 0001213900-23-019602.hdr.sgml : 20230313 20230313164609 ACCESSION NUMBER: 0001213900-23-019602 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230313 DATE AS OF CHANGE: 20230313 EFFECTIVENESS DATE: 20230313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Unicycive Therapeutics, Inc. CENTRAL INDEX KEY: 0001766140 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813638692 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-475696 FILM NUMBER: 23727905 BUSINESS ADDRESS: STREET 1: 4300 EL CAMINO REAL, SUITE 210 CITY: LOS ALTOS STATE: CA ZIP: 94022 BUSINESS PHONE: 650-384-0642 MAIL ADDRESS: STREET 1: 4300 EL CAMINO REAL, SUITE 210 CITY: LOS ALTOS STATE: CA ZIP: 94022 D 1 primary_doc.xml X0708 D LIVE 0001766140 Unicycive Therapeutics, Inc. 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA CALIFORNIA 94022 650-351-4495 DELAWARE None None Corporation true Shalabh Gupta 4300 El Camino Real, Suite 210 Los Altos CA CALIFORNIA 94022 Executive Officer Director Chief Executive Officer, President and Chairman of the Board of Directors John Townsend 4300 El Camino Real, Suite 210 Los Altos CA CALIFORNIA 94022 Executive Officer Chief Financial Officer John Ryan 4300 El Camino Real, Suite 210 Los Altos CA CALIFORNIA 94022 Director Sandeep Laumas 4300 El Camino Real, Suite 210 Los Altos CA CALIFORNIA 94022 Director Brigitte Schiller 4300 El Camino Real, Suite 210 Los Altos CA CALIFORNIA 94022 Director Gaurav Aggarwal 4300 El Camino Real, Suite 210 Los Altos CA CALIFORNIA 94022 Director Biotechnology Decline to Disclose 06b false 2023-03-03 false true true true false 0 EF Hutton, division of Benchmark Investments LLC 103792 None None 590 MADISON AVENUE 39TH FLOOR NEW YORK NY NEW YORK 10022 All States false 30190000 30190000 0 false 20 1650000 0 A cash fee equal to 5.5% of the gross proceeds. 0 false Unicycive Therapeutics, Inc. /s/ Shalabh Gupta Shalabh Gupta Chief Executive Officer 2023-03-13